Using FDA’s New Drug Development Tool: Start With Narrow Context Of Use
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As FDA gains experience with its new Drug Development Tool qualification process, the agency has found that a narrowly defined patient population and condition-specific measures are preferable.
You may also be interested in...
Biomarkers Qualification: Can FDA Get Rolling Before A Push From Congress?
FDA has been reluctant to lay out evidentiary standards for biomarker qualification, but its call for information on promising candidates may be an initial step toward creating such a framework.
Catalyzing Sarcopenia Drug Development: Identifying Outcomes, Defining Disease
FDA’s patient-focused drug development initiative and its Drug Development Tool for qualifying endpoints are galvanizing efforts to establish sarcopenia as an indication for clinical development in what could be a very significant market of elderly patients with weakness and functional disability.
Catalyzing Sarcopenia Drug Development: Identifying Outcomes, Defining Disease
FDA’s patient-focused drug development initiative and its Drug Development Tool for qualifying endpoints are galvanizing efforts to establish sarcopenia as an indication for clinical development in what could be a very significant market of elderly patients with weakness and functional disability.